Valneva SE faces a critical operational crisis, evidenced by a -26.5% year-over-year revenue decline in Q2 2026 and a gross margin collapse to 4.6%, which suggests severe pricing pressure or an unfavorable product mix.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.40-42.9% vs -$0.28 | $40M-16.4% vs $48M |
Q2 2026 May 13, 2026 | -$0.42-100.0% vs -$0.21 | $36M-33.8% vs $55M |
Q2 2026 Mar 16, 2026 | -$0.68-293.1% vs -$0.17 | $56M+6.5% vs $52M |
Q4 2025 Nov 20, 2025 | -$0.61-103.3% vs -$0.30 | $34M-29.5% vs $49M |
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026.
Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at upcoming investor conferences in the United States and Europe.
Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for travelers by the United Kingdom's (UK) Commission on Human Medicines (CHM), the UK marketing authorization for IXCHIQ® has been revoked by the Medicines and Healthcare products Regulatory Agency (MHRA). The decision was based on a review of previous safety data and was not associated with any newly identified safety signal. It does not affect the product licenses for IXCHIQ® in the EU, Canada, Brazil, or other territories where IXCHIQ® is currently marketed.
Valneva (NASDAQ: VALN - Get Free Report) and Septerna (NASDAQ: SEPN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability. Insider and Institutional Ownership 11.4% of Valneva shares are
Benchmark VALN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Valneva SE (VALN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.51 | $522.48M | -2.96 | 3% | -110.21% | -152.63% | — | |
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $0.34 | $12.38M | -1.62 | -64.74% | -219.5% | -2918.1% | — | |
| $8.64 | $9.05B | -9.14 | 668.31% | -598.56% | — | — | |
| $3.10 | $222.34M | -80.94 | -31.8% | -5.14% | -1.53% | 19.42% | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% |
Valneva SE (VALN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when VALN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Valneva SE (VALN) stock FAQ — growth, dividends, profitability & financials explained
Valneva SE (VALN) reported $143.5M in revenue over the trailing twelve months. Revenue was $174.7M in fiscal year 2025. That is 5701% more than the $3.0M of fiscal year 2005.
Valneva SE (VALN) revenue fell by 26.9% over the trailing twelve months, compared with the twelve months before.
No. Valneva SE (VALN) reported a net loss of $158.2M over the trailing twelve months.
Valneva SE (VALN) had a return on equity (ROE) of -152.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Valneva SE (VALN) had negative free cash flow of $85.7M over the trailing twelve months.
